Skip to main content
Equibles
AUPH logo

AUPH · Aurinia Pharmaceuticals Inc. · Metrics

Track AUPH — free

Use AUPH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AUPH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$16.56 +0.42 (+2.60%) At close · Nov 3 Play latest call Q4 2025 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$2.22B
Shares
134.00M
Volume · Nov 3 1.18M Avg daily vol (3M) 922.18K

AUPH metrics

96 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$16.56
Market cap
$2.22B

Price action

20 metrics
Price change (1W)
-5.3%
Price change (30D)
+2.7%
Price change (3M)
+10.8%
Price change (6M)
+2.3%
Price change (YTD)
+1.2%
Price change (1Y)
+22.6%
Trailing year
Price change (5Y)
-49.6%
52-week high
$18.62
52-week low
$13.17
Change from 52-week high
-13.3%
Change from 52-week low
+22.6%
Annualized volatility
36.7%
Annualized volatility (3M)
33.1%
Beta
0.6
RSI (14D)
42.4
Price vs SMA 50
-2.0%
Price vs SMA 200
+3.1%
Avg volume (3M)
925,564
Relative volume
1.7
Average dollar volume
$15.04M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
134.00M

Valuation

12 metrics
P / E (TTM)
7.0
Trailing earnings · reciprocal yield 14.2%
PEG ratio
—
EV / revenue
6.8×
reciprocal yield 14.8%
EV / EBITDA
12.4×
reciprocal yield 8.1%
EV / EBIT
13.9×
reciprocal yield 7.2%
P / sales
6.7×
reciprocal yield 14.9%
P / book
3.3
reciprocal yield 30.4%
FCF yield
—
TTM · current market cap
Buyback yield
3.5%
P / FCF
—
P / operating cash flow
12.2
reciprocal yield 8.2%
Earnings yield
14.5%

Historical valuation

8 metrics
P / E historical average (3Y)
31.9×
reciprocal yield 3.1%
P / E historical average (5Y)
31.9×
reciprocal yield 3.1%
EV / revenue historical average (3Y)
4.1×
reciprocal yield 24.3%
EV / revenue historical average (5Y)
10.5×
reciprocal yield 9.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
3.5%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-02-26

Profitability

9 metrics
Gross margin
90.6%
Operating margin
48.6%
Trailing 12 months
Net margin
97.7%
Gross profit (TTM)
$291.57M
Operating profit (TTM)
$156.37M
Net income (TTM)
$314.27M
Trailing 12 months
Diluted EPS (TTM)
$2.29
FCF margin
—
Effective tax rate
-88.1%

Per share

11 metrics
Revenue per diluted share (TTM)
$2.37
Gross profit per diluted share (TTM)
$2.14
Operating profit per diluted share (TTM)
$1.15
EBITDA per diluted share (TTM)
$1.29
Net income per diluted share (TTM)
$2.29
Operating cash flow per diluted share (TTM)
$1.30
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.35
Stock compensation per diluted share (TTM)
$0.11
Book value per share
$4.39

Growth

11 metrics
Revenue growth YoY
+13.9%
Year over year
Net income growth YoY
+0.5%
Revenue (TTM)
$321.74M
Trailing 12 months
EPS growth YoY
+0.0%
Shares change YoY
-0.6%
Year over year · fewer shares
Revenue CAGR (3Y)
+28.3%
Revenue CAGR (5Y)
+41.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
47.8%
Return on assets
38.1%
Debt / equity
0.1
Current ratio
6.1
EBITDA (TTM)
$175.72M
Free cash flow (TTM)
—
Quick ratio
5.7
Interest coverage
40.4
Net debt / EBITDA
0.1
Return on invested capital
—
Trailing 12 months
Net cash
−$9.39M
Latest balance sheet
Cash & equivalents
$45.79M
Total assets
$825.70M
Total debt
$55.18M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$177.16M
Capital expenditures (TTM)
—
R&D (TTM)
$48.03M
SG&A (TTM)
—
Stock compensation (TTM)
$14.82M
R&D / revenue
14.9%
Stock compensation / revenue
4.6%

Ownership (13F)

9 metrics
13F filers
285
13F filer change QoQ
+20
Institutional ownership
60.2%
Conviction holders (share of 13F filers)
0.7%
Crowding (high-turnover and private-fund holders)
21.6%
Private-fund adviser ownership
19.9%
Active holders' share change QoQ
-0.3%
Holder tenure
13.2
Price vs estimated holder cost
+56.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.3%

Short interest

3 metrics
Short interest
5.8%
Latest settlement · 9.0 days to cover
Days to cover
9.0d
Short-squeeze score
68 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$546,373
Insider-sentiment score
38 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1600620 CUSIP 05156V102 13F (30d) 91 filings 79 filers Visit website Investor relations